CODX Co-Diagnostics, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1692415 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY69.1%
TTM net income YoY-47.5%
TTM EPS YoY60.1%
Revenue 3-yr CAGR-43.1%
Net income 3-yr CAGR—
Margins
Gross margin20.3%
Operating margin-5,614.3%
Net margin-5,527.6%
FCF margin-3,165.7%
EBITDA margin-5,504.0%
Returns
ROE-194.5%
ROA-165.0%
ROIC (approx.)-207.8%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets26.3%
Debt / equity0.00x
Current ratio0.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.57x
Accruals ratio-71.6%
Payout ratio—
Capex / revenue35.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $622,489 | $3.92M |
| Cost of revenue | $222,377 | $999,124 |
| Gross profit | $400,112 | $2.92M |
| R&D expense | $19.14M | $20.98M |
| SG&A expense | $9.06M | $16.16M |
| Operating income | -$50.17M | -$40.08M |
| Pretax income | -$48.51M | -$37.58M |
| Income tax | -$1.62M | $57,368 |
| Net income | -$46.90M | -$37.64M |
| EBITDA | -$49.06M | -$38.70M |
| EPS (basic) | -35.25 | -37.22 |
| EPS (diluted) | -35.25 | -37.22 |
| Weighted avg. shares (diluted) | 1.33M | 1.01M |
| Balance sheet | ||
| Cash & equivalents | $11.88M | $2.94M |
| Short-term investments | — | $26.81M |
| Receivables | $190,375 | $132,570 |
| Inventory | $992,397 | $1.07M |
| Current assets | $13.69M | $32.29M |
| PP&E, net | $2.27M | $2.76M |
| Intangibles | $7.22M | $26.10M |
| Total assets | $24.74M | $63.56M |
| Current liabilities | $3.54M | $7.32M |
| Total liabilities | $4.11M | $9.69M |
| Shareholders' equity | $20.63M | $53.88M |
| Shares outstanding | 2.10M | 1.10M |
| Cash flow statement | ||
| Operating cash flow | -$29.14M | -$29.16M |
| Capital expenditure | $700,047 | $748,352 |
| Free cash flow | -$29.84M | -$29.90M |
| Investing cash flow | $26.27M | $17.07M |
| Financing cash flow | $11.81M | $103,914 |
| Depreciation & amortization | $1.11M | $1.38M |
| Stock-based compensation | $2.25M | $5.43M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.